News & Clinical Evidence

"With this new full-body PNS indication and long-term clinical evidence, we're expanding access for more patients who previously had limited treatment options, providing them potential relief from chronic pain through our innovative, long-term Freedom^® PNS System."

- Aure Bruneau, Chief Executive Officer of Curonix

“Sure Med’s platform seamlessly integrates within the established healthcare workflow and is ideal for collecting vital information on our Freedom PNS technology for patients who endure debilitating chronic pain. This partnership supports Curonix’s strategy to build off of an already robust Freedom PNS body of evidence and reinforces our commitment to educating healthcare professionals, patients, and insurers on its safe and effective use.”

- Colleen DeSantis, Vice President of Clinical and Reimbursement for Curonix

“Our mission at Curonix is to ensure that patients have access to innovative therapies that help free them from chronic pain and live a healthier life for an even better future.” This independent real-world application study further corroborates that our Freedom PNS System is a must-have option for healthcare professionals who want to treat their patients with a therapy that results in both positive outcomes and sustained pain relief.”

- Aure Bruneau, Chief Executive Officer of Curonix

“Curonix is committed to advancing patient access to innovative therapies. The CPT codes descriptors clarification for PNS and SCS procedures provides additional clarity for physicians and their dedicated teams. Additional real world clinical data continues to be published about the benefits of our Freedom products (Journal of Pain Research), and we remain committed to providing products to free those suffering chronic, debilitating pain.”

- Aure Bruneau, Chief Executive Officer of Curonix

“Our focus is always on getting patients back to living their lives free from chronic pain. The results of this study further corroborate that Freedom PNS allows patients to live life again, to sleep and walk with significantly reduced pain without relying solely on medication for pain relief. This is a must have solution for physicians looking to incorporate peripheral nerve stimulation with positive results into their practices.”

- Chris Valois, Chief Marketing & Strategy Officer of Curonix

“We are just getting started! Curonix is a new company that was formed to deliver much-needed non-opioid chronic pain relief with our innovative HF-EMC technology platform. We are committed to serving our customers and patients and are focused on continued product development, medical and patient education and clinical studies. We also continue to invest in our quality and regulatory systems to ensure that our products meet all global quality, regulatory and compliance standards.”

- Aure Bruneau, Chief Executive Officer of Curonix

Kai McGreevy, MD
Keilana McGreevy
Published Date: May/June 2024

Earl Kilbride, MD
Lane Kilbride
Published Date: March 31, 2024

J. Lance LaFleur, MD
Published Date: October 31, 2023

Anton Früh
Tarik Alp Sargut
Abdelhalim Hussein
Bartolomäus Muskala
Anja Kuckuck
Melanie Brüßeler
Peter Vajkoczy
Simon Bayerl
Published: September 20, 2023

Silky Patel, MD
Alaa Abd-Elsayed, MD
Published Date: July 31, 2023

Ryan Pollina, MD
Gabriela Betanzons
Alaa Abd-Elsayed, MD, MPH, CPE
Published: May 27, 2023

Alaa Abd-Elsayed, MD, MPH, CPE
Robert Moghim, MD
Published Date: February 23, 2023

Robert Bolash, MD,
Michael Creamer, DO
Richard Rauck, MD
Payam Vahedifar, MD
Aaron Calodney, MD
Ira Fox, MD
Cuneyt Özaktay, MD
Published: January 2022